Delivering Breakthrough Solutions
in Oncology Treatment
Learn More About How Byondis is Pioneering a New Generation of Antibody-Drug Conjugates
Get to know us
Swipe
Pipeline - Promising, novel, wholly-owned ADC technology platforms
Platforms
Modalities
Targets
Indications
Discovery
Preclinical
Clinical
Novel Platforms and Targeting Modalities
undisclosed
undisclosed
Oncology
Our Science is delivering diversity, selectivity and a wider therapeutic index through wholly owned platform
Novel targeting, broad range of payloads and optimized linker technologies Leveraging our unique platform, fully-integrated discovery, development and manufacturing capabilities to efficiently advance our proprietary pipeline of novel ADCs that deliver selectivity, diversity and widen the therapeutic index for treatment.
R&D and Manufacturing - Fully integrated in-house R&D and manufacturing from discovery to development to commercial supply
In-House R&D
Fully integrated, in-house drug discovery, development & in-house world-class manufacturing facilities
